Neurocrine Biosciences
NBIX
#1464
Rank
S$19.95 B
Marketcap
S$196.35
Share price
-1.19%
Change (1 day)
7.80%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2026 (TTM): S$8.61

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is S$8.55. In 2025 the company made an earnings per share (EPS) of S$6.14 an increase over its 2024 EPS that were of S$4.31.

EPS history for Neurocrine Biosciences from 2012 to 2026

Annual EPS

Year EPS Change
2026 (TTM)S$8.6140.23%
2025S$6.1442.6%
2024S$4.3133.07%
2023S$3.2457.76%
2022S$2.0569.47%
2021S$1.21-78.21%
2020S$5.56990%
2019S$0.5181.82%
2018S$0.28-113.5%
2017S-$2.080.62%
2016S-$2.0657.28%
2015S-$1.3125.61%
2014S-$1.0518.84%
2013S-$0.88-1085.71%
2012S$0.08922

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
S$1.67-80.48%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
S$2.62-69.35%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
S$35.97 320.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Repligen
RGEN
S$1.17-86.29%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
S-$2.59-130.25%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
S$5.24-38.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Palatin Technologies
PTN
S-$9.62-212.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
S$2.43-71.61%๐Ÿ‡ฌ๐Ÿ‡ง UK